+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Oncology Based In-Vivo CRO Market by Services, Indication, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5888779
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Oncology Based In-Vivo CRO Market grew from USD 1.27 billion in 2023 to USD 1.41 billion in 2024. It is expected to continue growing at a CAGR of 11.34%, reaching USD 2.70 billion by 2030.

The Oncology Based In-Vivo CRO (Contract Research Organization) market revolves around providing preclinical and clinical trial services for oncological research, helping pharmaceutical and biotech companies in drug discovery and development. Its scope is defined by services such as in vivo oncology pharmacology, toxicology studies, and the evaluation of treatment efficacy in animal models. The necessity of this market is driven by the increasing prevalence of cancer, demanding innovative and effective therapeutic solutions. Oncology CROs offer specialized applications including toxicity studies, pharmacokinetic and pharmacodynamic assessments, and efficacy screenings, which are crucial for the development of new cancer treatments. Major end-users include pharmaceutical companies, biotechnology firms, and research institutions seeking support in accelerating drug development timelines and ensuring regulatory compliance.

Key growth factors influencing the market include rising cancer incidence, technological advancements in oncology research tools, and increasing R&D investments from pharmaceutical companies. Moreover, the push for personalized medicine and targeted therapies is opening potential opportunities, particularly in the fields of biologics and immuno-oncology. Companies looking to capitalize should focus on expanding service portfolios with state-of-the-art technologies like CRISPR, AI-based analytics, and big data integration to enhance precision and efficiency. However, challenges such as stringent regulatory guidelines, high operational costs, and complex ethical considerations in animal research pose limitations to market growth.

Potential areas of innovation include developing more predictive and translational animal models, integrating automated systems for data handling, and personalized approaches to study design to improve reproducibility and relevance to human cancers. Collaboration between CROs and academic institutions can foster an innovative environment for breakthrough discoveries. The market nature is dynamic, characterized by rapid technological evolution and a competitive landscape where the ability to adapt and incorporate cutting-edge technologies significantly influences success. Overall, oncology-focused In-Vivo CROs must prioritize advanced research methodologies and strategic partnerships to maintain competitiveness and address unmet needs in the oncology therapeutics field.

Understanding Market Dynamics in the Oncology Based In-Vivo CRO Market

The Oncology Based In-Vivo CRO Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing incidence of cancer and need for effective drug discovery
    • Rising need for optimized and efficient oncology clinical trial activities
    • Government initiatives encouraging personalized medicine
  • Market Restraints
    • Concerns associated with data security and privacy
  • Market Opportunities
    • Advancements in oncology-based in-vivo technologies with data analytics and AI
    • Expansion of oncology CRO services for biomarker development
  • Market Challenges
    • Limitations of regulatory compliance of oncology trials

Exploring Porter’s Five Forces for the Oncology Based In-Vivo CRO Market

Porter’s Five Forces framework further strengthens the insights of the Oncology Based In-Vivo CRO Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Oncology Based In-Vivo CRO Market

External macro-environmental factors deeply influence the performance of the Oncology Based In-Vivo CRO Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Oncology Based In-Vivo CRO Market

The Oncology Based In-Vivo CRO Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Oncology Based In-Vivo CRO Market

The Oncology Based In-Vivo CRO Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Oncology Based In-Vivo CRO Market

The Oncology Based In-Vivo CRO Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology Based In-Vivo CRO Market, highlighting leading vendors and their innovative profiles. These include Altogen Labs, Cellvax, SAS, Charles River Laboratory, Crown Bioscience, Cyagen Biosciences, Evotec SE, Explicyte by Immusmol SAS Company, Icon PLC, Imavita, IVRS AB, Laboratory Corporation of America Holdings, Melior Discovery, Noble Life Sciences, Pharmaron, Pharmatest Services, Reaction Biology by Copeba, Redoxis AB, Taconic Biosciences, Inc., The Jackson Laboratory, and XenTech.

Market Segmentation & Coverage

This research report categorizes the Oncology Based In-Vivo CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Services
    • Biomarker Development
    • Clinical Trial Management
    • Pharmacokinetics Studies
    • Preclinical Studies
  • Indication
    • Hematological Malignancies
    • Rare Cancer
    • Solid Tumor
  • End-User
    • Academic & Research Institutes
    • Biotechnology Companies
    • Pharmaceutical Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of cancer and need for effective drug discovery
5.1.1.2. Rising need for optimized and efficient oncology clinical trial activities
5.1.1.3. Government initiatives encouraging personalized medicine
5.1.2. Restraints
5.1.2.1. Concerns associated with data security and privacy
5.1.3. Opportunities
5.1.3.1. Advancements in oncology-based in-vivo technologies with data analytics and AI
5.1.3.2. Expansion of oncology CRO services for biomarker development
5.1.4. Challenges
5.1.4.1. Limitations of regulatory compliance of oncology trials
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Oncology Based In-Vivo CRO Market, by Services
6.1. Introduction
6.2. Biomarker Development
6.3. Clinical Trial Management
6.4. Pharmacokinetics Studies
6.5. Preclinical Studies
7. Oncology Based In-Vivo CRO Market, by Indication
7.1. Introduction
7.2. Hematological Malignancies
7.3. Rare Cancer
7.4. Solid Tumor
8. Oncology Based In-Vivo CRO Market, by End-User
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Biotechnology Companies
8.4. Pharmaceutical Companies
9. Americas Oncology Based In-Vivo CRO Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Oncology Based In-Vivo CRO Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Oncology Based In-Vivo CRO Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ONCOLOGY BASED IN-VIVO CRO MARKET RESEARCH PROCESS
FIGURE 2. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ONCOLOGY BASED IN-VIVO CRO MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ONCOLOGY BASED IN-VIVO CRO MARKET DYNAMICS
TABLE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACOKINETICS STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RARE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 31. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 33. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 34. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 35. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 48. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 51. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 57. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 75. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 85. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 88. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 91. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 94. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 97. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 103. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 112. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 115. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 118. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 130. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 139. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2023
TABLE 148. ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Oncology Based In-Vivo CRO Market, which are profiled in this report, include:
  • Altogen Labs
  • Cellvax, SAS
  • Charles River Laboratory
  • Crown Bioscience
  • Cyagen Biosciences
  • Evotec SE
  • Explicyte by Immusmol SAS Company
  • Icon PLC
  • Imavita
  • IVRS AB
  • Laboratory Corporation of America Holdings
  • Melior Discovery
  • Noble Life Sciences
  • Pharmaron
  • Pharmatest Services
  • Reaction Biology by Copeba
  • Redoxis AB
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • XenTech

Methodology

Loading
LOADING...

Table Information